With an increasingly aging population, health care providers will treat a higher number of
patients with cognitive impairment. Identifying cognitive impairment and intervening early …

Biomarkers for predicting Alzheimer's disease (AD) are advancing and their implementation
in various healthcare systems is imminent. There is a need for ethical standards addressing …

Abstract Purpose of Review People with isolated REM (rapid eye movement) sleep behavior
disorder (iRBD) have a high lifetime risk of developing a neurodegenerative disease …

Introduction Given the growing number of Alzheimer's Disease and Alzheimer's Disease
Related Dementias (AD/ADRD) genomics research projects and the vulnerabilities of study …

Background: Although African Americans experience the highest risk of Alzheimer's disease
(AD), they are dramatically underrepresented in preclinical biomarker research. This is …

Genome sequencing (GS) has demonstrated high diagnostic yield in pediatric patients with
complex, clinically heterogeneous presentations. Emerging evidence shows generally …

Abstract Byu d Mar 25 (BM25) has been verified to have neuroprotective effects in
Alzheimer's disease (AD) mice. However, the molecular mechanism remains unclear. We …

The availability and cost of next‐generation sequencing (NSG) now allow testing large
numbers of genes simultaneously. However, the gold standard for predictive testing has …

Globally, 47 million individuals live with dementia, and by 2050, that number is expected to
more than triple (to 131 million). One of the main causes of increasing dementia is …

People being evaluated by a neuropsychologist for neurocognitive disorders may also be
undergoing testing or treatment by primary care physicians, neurologists, or psychiatrists …